X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Brenzavvy (bexagliflozin) is an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Lead Product(s): Bexagliflozin
Therapeutic Area: Endocrinology Product Name: Brenzavvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2024
Details:
Under the agreement, IPC gains distribution rights for Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, used for the treatment of adults with type 2 diabetes mellitus.
Lead Product(s): Bexagliflozin
Therapeutic Area: Endocrinology Product Name: Brenzavvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Independent Pharmacy Cooperative
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 01, 2024
Details:
Under the collaboration, SmithRx will offer access to Brenzavvy (bexagliflozin), a sodium glucose transporter 2 (SGLT2) inhibitor and TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes.
Lead Product(s): Bexagliflozin
Therapeutic Area: Endocrinology Product Name: Brenzavvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SmithRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 17, 2023
Details:
Brenzavvy (bexagliflozin), a SGLT2 inhibitor which helps in reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lead Product(s): Bexagliflozin
Therapeutic Area: Endocrinology Product Name: Brenzavvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
Brenzavvy™ (bexagliflozin) is a SGLT2 inhibitor thus, reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Lead Product(s): Bexagliflozin
Therapeutic Area: Endocrinology Product Name: Brenzavvy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
